Core Monitored Gases: High-Risk Gases in Pharmaceutical Processes

The gas risks in the pharmaceutical industry span the entire workflow of active pharmaceutical ingredient (API) production, formulation processing, biopharmaceutical manufacturing, laboratory research, and utility systems (e.g., boiler rooms, wastewater treatment), primarily involving the following five categories of gases:

1. Flammable and Explosive Gases: Potential Threats in Processes and Energy Use

● Hydrogen (H₂): Widely used as a reducing agent in API synthesis (e.g., nitro compound reduction, catalytic hydrogenation reactions). Leaks from reactors or hydrogen storage tanks can accumulate in reaction zones or equipment bottoms. Hydrogen has an extremely wide explosive limit (4%–75%), and even low concentrations can trigger explosions.

● Methane (CH₄): Some pharmaceutical companies use natural gas (primarily methane) as fuel for boilers or heating equipment. Leaks from pipelines or valves may lead to accumulation.

● Organic Solvent Vapors (e.g., Acetone, Ethanol): Heavily used in extraction, purification, or cleaning processes. Their vapors, if emitted due to ventilation failures or solvent spills, can form explosive mixtures with air (e.g., acetone: explosive limit 2.5%–13%).

2. Toxic and Hazardous Gases: Direct Risks from Reactions and Handling

● Ammonia (NH₃): Used in API synthesis (e.g., amide formation), cleanroom disinfection (e.g., pre-sterilization of sterile production areas), or refrigeration systems (e.g., cold storage ammonia refrigeration). High-concentration ammonia (odor threshold ~50 ppm, but irritating to the respiratory tract at ≥50 ppm and life-threatening at ≥300 ppm) is highly corrosive and irritating.

● Chlorine (Cl₂): Employed in some API syntheses (e.g., chlorination of antibiotic intermediates) or wastewater treatment (disinfection). It is highly toxic (inhaling small amounts can damage the respiratory tract and lungs, with a lethal concentration of ~3000 ppm) and strongly oxidizing.

● Hydrogen Sulfide (H₂S): May be produced during the handling of sulfur-containing raw materials (e.g., certain natural drug extracts) or anaerobic wastewater treatment. Low concentrations (≥10 ppm) produce a "rotten egg" odor, while high concentrations (≥100 ppm) rapidly numb the olfactory nerves, leading to fatal poisoning (threshold limit value TLV-TWA: 10 ppm).

● Special Toxic Gases (e.g., Phosgene (COCl₂), Phosphine (PH₃)): Involved in synthesizing certain API intermediates (e.g., pesticide intermediates, anticancer drugs), these gases are extremely toxic (phosgene: lethal concentration ~1000 ppm; phosphine: 10–50 ppm).

3. Anesthetic Gases and Volatile Organic Compounds (VOCs): Hidden Risks in Special Processes and Environments

● Anesthetic Gases (e.g., Nitrous Oxide (N₂O), Isoflurane, Sevoflurane): Used in drug clinical trials (e.g., analgesia research), biological laboratories (animal anesthesia), or special formulation production (e.g., inhaled drugs). Long-term exposure (e.g., laboratory personnel exposed to low-concentration nitrous oxide) can cause neurotoxicity (e.g., vitamin B12 deficiency, nervous system damage).

● VOCs (e.g., Methanol, Benzene Series, Acetone, Dichloromethane): Originating from organic solvents (extraction, purification), cleaning agents (equipment cleaning), packaging materials (e.g., inks, adhesives), or laboratory reagents, long-term exposure may cause operators headaches, dizziness, liver/kidney damage, and some VOCs (e.g., benzene) are known carcinogens. High-concentration VOCs can also interfere with cleanroom air quality, affecting drug quality (e.g., particulate contamination in injectables).

4. Oxygen (O₂) Concentration Anomalies: Risks in Confined Spaces

In enclosed reactors, bioreactors, or cleanroom ventilation systems, oxygen may be consumed (e.g., microbial anaerobic fermentation, chemical reactions consuming oxygen) or displaced by inert gases (e.g., nitrogen), creating oxygen-deficient environments (O₂<19.5% VOL) that threaten personnel safety.